IL-2 during in vitro priming promotes subsequent engraftment and successful adoptive tumor immunotherapy by persistent memory phenotypic CD8+ T cell

O. F. Bathe, N. Dalyot-Herman, T. R. Malek

Research output: Contribution to journalArticle

17 Scopus citations


Adoptive T cell tumor immunotherapy potentially consists of two protective components by the transferred effector cells, the immediate immune response and the subsequent development of memory T cells. The extent by which adoptively transferred CD8+ CTL are destined to become memory T cells is ambiguous as most studies focus on the acute effects on tumor shortly following adoptive transfer. In this study we show that a substantial fraction of the input CTL develop into memory cells that reject a s.c. tumor challenge. The use of exogenous IL-2 or a combination of IL-2 and IL-4, but not solely IL-4, during the ex vivo culture for the CTL inoculation was necessary for efficient development of CD8+ memory T cells. Thus, an important component of adoptive immunotherapy using CTL is the production of CD8+ Ag-specific memory cells which is primarily favored by IL-2 receptor signaling during ex vivo generation of the effector CTL.

Original languageEnglish (US)
Pages (from-to)4511-4517
Number of pages7
JournalJournal of Immunology
Issue number8
StatePublished - Oct 15 2001


ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this